Bristol Myers Squibb (NYSE: BMY) reported its Q3 results last month, with revenues meeting and earnings beating the street estimates, and we believe that BMY stock is .
Returning to the pre-inflation shock level of over $80 means that BMY stock will have to gain more than 35% from here, and we think it will likely materialize over time.